Soluble Alkaline Phosphatase Constructs for Hypophosphatasia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hypophosphatasia, a rare skeletal disease characterized by impaired bone mineralization, are inadequate, leading to severe symptoms including skeletal deformities, short stature, and premature tooth loss, with no effective therapeutic options available to address the underlying alkaline phosphatase deficiency.
Innovation Solution
Development of a polypeptide comprising a secretion signal peptide, an alkaline phosphatase sequence, and a GPI anchor, encoded by a lentiviral vector, which is capable of catalyzing the formation of hydroxyapatite crystals and cleaving inorganic pyrophosphate, designed to be expressed in host cells for therapeutic delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for hypophosphatasia, then current therapeutic options are available, but they are inadequate and do not effectively address the underlying alkaline phosphatase deficiency
Solution Approach 1:
The patent extracts and replaces the defective alkaline phosphatase enzyme by introducing a functional TNSALP gene via lentiviral vector, separating the therapeutic function from the defective host protein synthesis machinery
Solution Approach 2:
The lentiviral vector serves as an intermediary carrier that delivers the functional TNSALP gene to host cells, enabling expression of the therapeutic enzyme without directly replacing the defective protein
2Reliability
If the polypeptide is designed with specific functional domains, then catalytic activity is improved, but the molecular complexity increases
Solution Approach 1:
The TNSALP polypeptide is designed with multi-functional domains including signal peptide for secretion, catalytic domain for pyrophosphate cleavage, and GPI anchor for cellular anchoring, allowing a single protein to perform multiple essential functions
Solution Approach 2:
The polypeptide is segmented into distinct functional regions: N-terminal signal peptide (A), catalytic alkaline phosphatase domain (B), GPI anchor sequence (C), and variable regions (D, E), enabling modular design and expression
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polypeptide effectively addresses the alkaline phosphatase deficiency by promoting bone mineralization, potentially alleviating symptoms of hypophosphatasia and improving bone health in affected individuals.
Implementation Method 1
the polypeptide is catalytically competent to allow formation of hydroxyapatite crystals, such as in bone
Implementation Method 2
the polypeptide is capable of catalyzing the cleavage of inorganic pyrophosphate
Implementation Method 3
the polypeptide is capable of catalyzing the cleavage of inorganic pyrophosphate
Data Source
AI summary
The present disclosure is directed to polypeptides, such as polypeptides comprising an alkaline phosphatase and a bone-targeting moiety. Also disclosed are expression vectors, such as lentiviral expression vectors, including a nucleotide sequence encoding a polypeptide. Also disclosed are methods of treating hypophosphatasia or treating, mitigating, or preventing one or more symptoms of hypophosphatasia by administering to a subject in need of treatment thereof the disclosed polypeptides or host cells transduced to express any of the disclosed polypeptides.